Medication-Assisted Treatment (MAT) for Opioid Use Disorder: When the Carrier Denies Buprenorphine, Methadone, or Vivitrol

There are three FDA-approved medications for opioid use disorder, the three of them function differently, and the denial letter does not always know it is denying the wrong one. The pharmacy benefit denial that arrived at a 36-year-old utility lineman's home in Cincinnati in February cited a step-therapy rule requiring "failure of buprenorphine before consideration of extended-release naltrexone." The patient had been on buprenorphine-naloxone for 22 months following an opioid-related hospitalization, had transitioned off the medication six weeks earlier under his addiction medicine specialist's guidance, and was now being prescribed extended-release naltrexone (Vivitrol) to support relapse prevention as he returned to work. The transition had been clinically deliberate. The carrier reviewer's worksheet recorded none of that. It recorded a step-therapy gate written for treatment-naive patients, applied to a patient who had completed the prior step.

This is the most common shape of a MAT denial: a coverage rule that may be defensible in the abstract is applied to a clinical picture it was not designed for. Medication for opioid use disorder, formerly called medication-assisted treatment and now increasingly called medications for opioid use disorder (MOUD), is governed by a layered framework that includes the SUPPORT for Patients and Communities Act of 2018, the 2024 amendments to 42 CFR Part 8 (the federal opioid treatment program rule), 42 CFR Part 2 confidentiality, MHPAEA parity, and the standard commercial-coverage appeal frameworks. The clinical-society standard is the American Society of Addiction Medicine's National Practice Guideline for the Treatment of Opioid Use Disorder, currently the 2020 Focused Update.

This article walks through the three FDA-approved medications and the clinical role of each, the most common denial patterns and the appeal anchors, the SUPPORT Act and Part 8 framework, the parity overlay, and the procedural posture for a MAT appeal. It is a clinical-procedural piece. It does not address policy debates around MAT. It addresses the working mechanics of overturning a coverage denial.

The three medications

The FDA has approved three medications for opioid use disorder, each with a distinct mechanism, a distinct clinical role, and a distinct regulatory framework.

Methadone, a full opioid agonist, has been the primary OUD medication since the 1960s. Methadone for OUD is dispensed under federal regulations at 42 CFR Part 8 through certified opioid treatment programs (OTPs). The 2024 final rule revising 42 CFR Part 8, effective April 2, 2024, modernized the OTP framework with expanded take-home dosing flexibility, telehealth provisions, and broader admission criteria. Methadone for OUD outside the OTP framework remains restricted; methadone prescribed for pain management is a separate clinical and regulatory question.

Buprenorphine, a partial opioid agonist, is FDA-approved as buprenorphine-naloxone (Suboxone, Zubsolv, generic), buprenorphine monoproduct (Subutex, generic), and extended-release injectable buprenorphine (Sublocade, Brixadi). The Mainstreaming Addiction Treatment (MAT) Act of 2023, enacted as part of the Consolidated Appropriations Act of 2023, eliminated the X-waiver requirement that had previously limited buprenorphine prescribing. Any DEA-registered practitioner may now prescribe buprenorphine for OUD within the scope of their practice. The clinical framework remains anchored on the ASAM guideline.

Naltrexone, an opioid antagonist, is FDA-approved as extended-release injectable naltrexone (Vivitrol) for OUD. Naltrexone does not produce opioid agonist effects and does not require an opioid-treatment-program framework. It does require a documented opioid-free period before initiation (typically 7 to 14 days) to avoid precipitated withdrawal. The clinical role of naltrexone differs from methadone and buprenorphine; it is generally not appropriate for patients with ongoing opioid use.

The denial that applies a step-therapy rule across these three medications without recognizing their distinct clinical roles is the most common appeal target. ASAM's National Practice Guideline explicitly addresses the medication-selection framework and rejects the notion that the three medications are interchangeable along a single tier ladder.

The four denial patterns

The denials in MAT coverage fall into four principal patterns.

The first is the step-therapy denial. The carrier requires failure of one medication before approving another. The pattern is most defensible where the carrier requires buprenorphine before naltrexone for an opioid-tolerant patient (a clinically reasonable sequence). The pattern is least defensible where the carrier requires naltrexone before buprenorphine (clinically inappropriate for most opioid-tolerant patients), where the carrier requires step therapy that contradicts the patient's actual treatment history, or where the carrier applies a step rule to a stable maintenance patient.

The second is the prior-authorization denial on dosing. The carrier denies coverage of buprenorphine doses above a fixed ceiling (often 24 mg per day) without individualized review. ASAM's guideline addresses the dosing-flexibility question; dosing above the standard ceiling is appropriate in some clinical circumstances and the categorical cap is inconsistent with the society standard.

The third is the duration-of-treatment denial. The carrier limits maintenance treatment to a fixed period (often 12 months or 24 months) and then requires demonstration of "ongoing medical necessity" for continuation. ASAM and SAMHSA guidance both reject fixed-duration limits on MAT for OUD; the standard is "indefinite or until clinically appropriate."

The fourth is the level-of-care or facility denial. For methadone, this most commonly involves the OTP network or the OTP admission criteria; for injectable buprenorphine, the office-based administration framework; for inpatient or residential addiction treatment integrating MAT, the level-of-care decisions addressed in the residential mental health appeal article (cross-reference article 26).

What ASAM and SAMHSA actually say

The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder, in its 2020 Focused Update, articulates the clinical framework the appeal anchors on. The key principles relevant to coverage appeals include: all three FDA-approved medications are effective; medication selection should be individualized based on patient clinical factors, preference, and treatment history; methadone and buprenorphine are first-line for opioid-tolerant patients in active opioid use; naltrexone is appropriate for patients who have completed withdrawal; treatment duration should be indefinite or until clinically appropriate, with no arbitrary cap; dose should be optimized to clinical response, with adequate doses ranging higher than the historical ceilings; integration with behavioral support is recommended but should not be a precondition for medication access; psychosocial therapy is not a required precondition for medication.

SAMHSA's TIP 63, Medications for Opioid Use Disorder, complements the ASAM guideline and is the federal-agency consensus document. The 2024 Part 8 final rule and SAMHSA's accompanying guidance address the OTP-specific framework.

The U.S. Preventive Services Task Force has recommended screening for unhealthy drug use in adults, which connects MAT to the ACA's preventive-services framework for certain components of care.

The SUPPORT Act, the MAT Act, and the federal coverage framework

The SUPPORT for Patients and Communities Act of 2018 made several structural changes relevant to MAT coverage. Section 1006 expanded Medicare coverage of MAT, including the bundled-payment structure for opioid use disorder treatment services in opioid treatment programs at 42 CFR Part 410, Subpart H. The Section 1006 framework requires Medicare Advantage plans to cover MAT-related services consistent with the OTP bundled-payment structure.

The Section 1262 amendments addressed Medicaid coverage of SUD residential treatment (cross-reference article 26).

The Mainstreaming Addiction Treatment Act of 2023 eliminated the X-waiver requirement for buprenorphine prescribing and broadened the practitioner pool able to prescribe buprenorphine for OUD. The Act did not directly mandate insurance coverage but eliminated one structural barrier that had complicated access.

The federal essential health benefits framework under the ACA includes mental health and substance use disorder treatment as one of the ten essential health benefit categories. The specific scope of MAT coverage within that category is plan-design dependent but the categorical inclusion is mandated.

Exhibit 1: The three medications, the framework, and the appeal anchor

The clinical and regulatory pictures are easier to hold side by side.

| Medication | Mechanism | Dispensing framework | Appropriate population | Most common denial pattern | |---|---|---|---|---| | Methadone | Full opioid agonist | OTP only (42 CFR Part 8) | Opioid-tolerant patients in OUD treatment | OTP network/access; admission criteria | | Buprenorphine (SL film/tablet) | Partial agonist | Office-based by any DEA practitioner (post-MAT Act) | Opioid-tolerant patients in OUD treatment | Step therapy; dosing cap; duration limit | | Buprenorphine (XR injectable) | Partial agonist | Office-based administration | Stable maintenance patient or transition | Step therapy from SL; site of service | | Naltrexone (XR injectable) | Antagonist | Office-based administration | Post-withdrawal, motivated patient | Required as first-line inappropriately; opioid-free period |

Action title for designer: "Three medications, three frameworks, three appeal anchors. The denial that treats the three as interchangeable is the appeal that frames the most clearly."

Exhibit 2: ASAM principles and how they map to common denials

The clinical-guideline principles are the framework the appeal cites.

| ASAM principle | Corresponding denial pattern | Appeal anchor | |---|---|---| | All three FDA-approved medications are effective | Categorical exclusion of one medication | Society guidance; FDA approval | | Medication selection should be individualized | Single-medication formulary | Society guidance; clinical-record argument | | Methadone and buprenorphine are first-line for opioid-tolerant | Naltrexone-first step therapy | Society guidance; clinical inappropriateness | | Treatment duration indefinite or until clinically appropriate | Fixed-duration cap | Society guidance; non-arbitrary review standard | | Dose optimization to clinical response | Fixed dosing ceiling | Society guidance; individualized review | | Behavioral support recommended but not a precondition | Therapy-attendance precondition | Society guidance; access-not-conditional | | Psychosocial therapy not required as precondition | Counseling-attendance precondition | Society guidance |

Action title for designer: "The ASAM guideline is the working standard. Most MAT denial patterns map cleanly to ASAM principles the denial does not respect. The appeal cites the principle by name."

Exhibit 3: The parity overlay for MAT denials

The MHPAEA framework reaches MAT denials in specific structural ways. Article 13 in this corpus addresses the parity framework in detail; the table below summarizes the MAT-specific applications.

| MAT denial pattern | Medical-surgical analog | Parity question | |---|---|---| | Step therapy across MAT medications | Step therapy in medical-surgical drug classes (statins, antihypertensives) | Comparable evidentiary basis and stringency | | Dosing ceiling on buprenorphine | Dosing ceiling on comparable medical drug | Comparable evidentiary basis | | Duration limit on MAT maintenance | Duration limit on comparable medical maintenance therapy | Comparable evidentiary basis | | Prior-authorization on MAT initiation | Prior-authorization on comparable medical drug initiation | Comparable processes | | Counseling-attendance precondition | Behavioral-precondition for medical therapy | Comparable conditions | | OTP network adequacy | Specialist network adequacy | Comparable network standards |

Action title for designer: "The parity questions in MAT coverage are concrete. The 2024 Final Rule provides the document right; the appeal uses the produced (or non-produced) comparative analysis as evidence."

What makes this difficult in practice

MAT appeals run across three medications, four denial patterns, and three regulatory frameworks (ASAM National Practice Guideline, SAMHSA TIP 63, the SUPPORT Act / MAT Act / Part 8 framework) with the MHPAEA parity overlay layered on top. The mapped library Apellica has catalogued (more than two hundred carrier-by-denial-type cells, indexed at the bulletin level) each route MAT appeals through different pharmacy-benefit managers and different behavioral-health subcontractors, with step-therapy rules, dosing ceilings, duration limits, and OTP-network gates that vary by carrier and product line. A denial built against the patient's chart can read as defensible in the abstract; the rebuttal requires reading the chart against the carrier's specific bulletin.

The 30-day MHPAEA comparative-analysis request runs in parallel with the underlying appeal. The 42 CFR Part 2 confidentiality framework structures how SUD records are disclosed; the standard HIPAA authorization does not substitute. The expedited 72-hour track is essential when a gap in MAT medication is approaching because relapse risk runs on a clinical clock the carrier's review queue does not match. Procedural exhaustion missteps foreclose external review.

A step-therapy rule written for treatment-naive patients was applied to a patient who had completed the prior step. The rule was defensible in the abstract. The chart told a different story.

The work the desk does that a patient cannot

Apellica's reviewers work from a mapped library of over two hundred carrier-by-denial-type cells that tracks MAT coverage at every major commercial carrier, PBM, Medicare Advantage organization, and state Medicaid program. The desk maintains the ASAM National Practice Guideline, SAMHSA TIP 63, the 2024 Part 8 final rule, the MAT Act framework, and the current MHPAEA implementation guidance.

Same-day document-request and MHPAEA comparative-analysis letters go out with the correct CFR cite. Apellica's senior reviewers build the four-part evidence stack, plan-language citation, clinical facts drawn from the treating clinician's record and the medication-selection rationale, peer-reviewed and society evidence (ASAM, SAMHSA, FDA labeling), regulatory hook combining MHPAEA, Section 1006, and the FDA-approval framework, for every case. The 42 CFR Part 2 consent framework is preserved throughout. Expedited handling is requested where a gap in medication is approaching. A senior reviewer reads every appeal before it goes out.

Initial review is free. There is no upfront fee. Patients are not asked to pay anything until the carrier reverses the denial.

The 42 CFR Part 2 confidentiality framework, in the appeal context

42 CFR Part 2 governs the confidentiality of substance use disorder patient records. The framework is more restrictive than HIPAA in several respects, though the 2024 Part 2 amendments (effective February 2026) brought significant alignment with HIPAA for many purposes.

The appeal-context implication is that the SUD treatment records the appeal relies on are subject to specific consent requirements before they may be disclosed to the carrier or to any reviewer. The patient consent under 42 CFR Part 2 should specify the records being released, the recipient, the purpose of the disclosure, and the expiration of the consent. The standard HIPAA authorization does not substitute for Part 2 consent for SUD treatment records originating in Part 2-covered programs.

The 2024 amendments allow for a single written consent for treatment, payment, and operations purposes, which simplifies the appeal-context disclosure framework. The Substance Abuse and Mental Health Services Administration publishes implementation guidance.

Procedural deadlines and parallel filings

MAT denials follow the deadlines of the underlying plan. ACA-regulated plans: 180 days under 45 CFR 147.136(b). ERISA self-funded: 180 days under 29 CFR 2560.503-1(h). Medicare Advantage: 60 days under 42 CFR 422.582. Medicaid: state-specified fair-hearing timeframes under 42 CFR 431.220.

Pharmacy benefit denials follow the medical-appeal framework when the denial is administered as a medical-necessity denial. Where the denial is administered through the PBM as a formulary or step-therapy decision, the appeal route may run through the PBM with the same underlying procedural rights. The denial letter identifies the route; if unclear, both routes should be exhausted.

Expedited handling is appropriate where the clinical timeline supports it. For MAT, the urgency posture is often strong: a gap in MAT medication for an opioid-tolerant patient creates relapse risk. The expedite request cites the specific clinical reason.

The MHPAEA parity complaint runs in parallel. For ERISA plans, the Department of Labor's EBSA. For non-ERISA, the state insurance commissioner or CMS. Article 13 addresses the parallel filing framework in detail.

Where to ask for help

The American Society of Addiction Medicine, at asam.org, publishes the National Practice Guideline and provides clinician-facing resources. SAMHSA, at samhsa.gov, publishes TIP 63 and administers the federal SUD treatment framework, including the National Helpline at 1-800-662-HELP. The Legal Action Center, at lac.org, focuses on SUD coverage, parity, and confidentiality. NAATP (National Association of Addiction Treatment Providers), at naatp.org, supports treatment provider and patient navigation. The American Association for the Treatment of Opioid Dependence, at aatod.org, focuses on OTP-related coverage issues. The Department of Labor's EBSA at askebsa.dol.gov handles ERISA parity complaints. State insurance commissioners are indexed at content.naic.org/consumer.htm. Apellica, at apellica.com, prepares evidence-based appeal letters for MAT and SUD treatment coverage denials in all 50 states with no upfront fee.

What to do if you have a MAT denial right now

ASAM supplies the standards. SAMHSA supplies the federal-agency consensus. The FDA approvals supply the medication framework. The parity rule supplies the structural overlay. Most patients leave coverage on the table because reading the denial against all four is more procedural work than they can take on, especially when a medication gap is approaching.

The Cincinnati patient's appeal documented the completed buprenorphine course, cited ASAM's National Practice Guideline on the clinical role of extended-release naltrexone, and requested expedited review against the impending medication gap. The carrier approved the Vivitrol prescription before the next dose was due.

The Apellica model, briefly

Apellica prepares the evidence-based appeal letter for MAT and substance use disorder treatment coverage denials in all 50 states, at every level of the internal and external appeal process. The patient reviews and approves every word before submission and authorizes carrier communications under a HIPAA-compliant Assignment of Benefits and 42 CFR Part 2 consent. We are not a law firm. We are not a medical provider. We are not an insurance carrier. We are an independent administrative service that turns a denied claim into a properly documented appeal letter.

Our model is $0 upfront and a flat fee on successful recovery. If the appeal does not reverse, the patient owes nothing for the preparation work. Coverage extends to all 50 states, every commercial carrier, ERISA plans, Medicare Advantage, Medicare fee-for-service, Medicaid, TRICARE, and VA. A senior reviewer reads every case before it goes out.

About the author

Apellica is an independent appeal-preparation service for patients facing health-insurance denials. Mark Henderson is one of the senior reviewers on the desk. The firm operates from One World Trade Center in lower Manhattan and serves patients in all fifty states. Apellica is not a law firm and does not give legal advice. Reach the office at press@apellica.com, +1 (888) 777-6120, or apellica.com.

References

• American Society of Addiction Medicine, National Practice Guideline for the Treatment of Opioid Use Disorder, 2020 Focused Update.
• SAMHSA, Medications for Opioid Use Disorder, Treatment Improvement Protocol (TIP) 63.
• SUPPORT for Patients and Communities Act of 2018, Pub. L. 115-271.
• Section 1006 of the SUPPORT Act, Medicare OTP coverage.
• Section 1262 of the SUPPORT Act, Medicaid IMD pathway for SUD.
• Mainstreaming Addiction Treatment Act of 2023.
• 42 CFR Part 8. Federal Opioid Treatment Programs.
• 42 CFR Part 8 Final Rule (April 2, 2024).
• 42 CFR Part 410, Subpart H. Medicare OTP bundled payment.
• 42 CFR Part 2. Confidentiality of substance use disorder patient records.
• 42 CFR Part 2 amendments (effective February 2026).
• Mental Health Parity and Addiction Equity Act of 2008, 29 USC 1185a.
• 89 Fed. Reg. 77586 (Sept. 23, 2024). MHPAEA Final Rule.
• 29 CFR 2590.712. ERISA implementation of MHPAEA.
• FDA approvals for methadone, buprenorphine (Suboxone, Zubsolv, Subutex, Sublocade, Brixadi), and naltrexone (Vivitrol).
• U.S. Preventive Services Task Force, screening for unhealthy drug use.
• 45 CFR 147.136. Internal claims and appeals and external review.
• 29 CFR 2560.503-1. ERISA claims procedure.
• 42 CFR 422.582. Medicare Advantage reconsideration deadline.
• 42 CFR 422.584. Medicare Advantage expedited reconsideration.
• 42 CFR 431.220. Medicaid fair-hearing procedures.
• American Association for the Treatment of Opioid Dependence. aatod.org.
• Legal Action Center. lac.org.
• NAATP. naatp.org.
• Department of Labor, Employee Benefits Security Administration. askebsa.dol.gov.
• NAIC Consumer Information Source. content.naic.org/consumer.htm.